SCHEMBL4576852

SCHEMBL4576852

COc1ccc(NC(=O)CN2CCC(Cc3ccccc3)CC2)cc1

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.72
MEN1 O00255 1/20 0.72
KMT2A Q03164 1/20 0.72
CCR3 P51677 2/20 0.68
ACHE P22303 1/20 0.68
KDM4E B2RXH2 3/20 0.67
LMNA P02545 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
GRIN1 Q05586 1/20 0.66
GRIN2B Q13224 1/20 0.66
ALDH1A1 P00352 2/20 0.62
KCNA5 P22460 1/20 0.61
POLB P06746 1/20 0.60
TDP1 Q9NUW8 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4577591 0.89 SMN1; SMN2 (0.66) SMN1; SMN2MEN1KMT2ACCR3KDM4E
SCHEMBL28599359 0.88 KDM4E (0.71) SMN1; SMN2MEN1KMT2ACCR3KDM4E
SCHEMBL4414755 0.86 KDM4E (0.69) SMN1; SMN2MEN1KMT2AKDM4ELMNA
SCHEMBL31212419 0.85 ACHE (0.67) SMN1; SMN2MEN1KMT2ACCR3ACHE
SCHEMBL4578765 0.85 MEN1 (0.70) SMN1; SMN2MEN1KMT2AKDM4ELMNA
SCHEMBL13234951 0.84 SMN1; SMN2 (1.00) SMN1; SMN2MEN1KMT2ACCR3
Hydrochloric Acid SCHEMBL4577724 0.84 KDM4E (0.67) SMN1; SMN2MEN1KMT2AKDM4ELMNA
SCHEMBL4577307 0.84 KDM4E (0.67) SMN1; SMN2MEN1KMT2AACHEKDM4E
SCHEMBL4576715 0.83 LMNA (0.72) SMN1; SMN2MEN1KMT2AKDM4ELMNA
Hydrochloric Acid SCHEMBL4578881 0.83 KDM4E (0.66) SMN1; SMN2MEN1KMT2ACCR3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12139461-B1 Piperidine compounds as PDE5 inhibitors KING SAUD UNIVERSITY (SA) 2024-11-12 US disclosed
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 US disclosed
EP-1409477-B1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2008-09-17 EP disclosed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 US disclosed
EP-1409477-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2004-04-21 EP disclosed
WO-2003010159-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists GRIN1, GRIN2D, GRIN2C SMN1; SMN2 2793/4885MEN1 2584/4885KMT2A 1234/4885
US-12139461-B1 Piperidine compounds as PDE5 inhibitors PDE5A, PDE3A, PDE2A SMN1; SMN2 1809/4885MEN1 3740/4885KMT2A 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.